Table 2. Summary of studies investigating the efficacy and toxicity seen in OA treated with chemotherapy.

	Cancer type and patients included (age in years)	No. of patients	Survival outcomes		Toxicity outcomes
Smorenburg et al [4]	Breast >65	78	65–75 years old no differences		1. 65–75 years old no differences 2. >80 years old: Only one in ten patients completed chemotherapy
Begg et al [17]	Lung Breast Colorectal <65 versus >65	3,000 (Meta-analysis)	Equivalent response rates between <65 and >65 patients		1. No increase in frequency or severity of toxicity in >65 years old versus <65 years old 2. Compliance similar between both groups
Christman et al [18]	Breast <50 50–65 >65	40 60 70	PFS	OS	1. Toxicity frequency and severity same across groups 2. Same number of dose delays seen across groups
			9.1 months	17.9 months
			6.2 months	12.8 months
			7.2 months	14.2 months
Crivellari et al [19]	Breast <65 versus >65	299	Same PFS between groups		1. G3 toxicity 17% in >65 years old versus 7% in <65 years old 2. More of >65 years old group received less than expected doses
Hurria et al [20]	Lung, Gastrointestinal, Breast, Gynae Genitourinary >65	500	Not assessed		1. 53% of patients experienced G3–5 toxicity with 2% grade 5 toxicity
Extermann et al [21]	Any Cancer >70	518	Not assessed		1. 64% of patients experienced severe toxicity
Lund et al [22]	Colorectal <70 versus >70	529	1. No difference in age-adjusted disease-free survival (DFS) or 10 years mortality 2. Poor performance status across all ages led to worse DFS and 10 years mortality rates		1. No age-adjusted difference in G3–5 toxicity 2. Elderly patients more frequently received single versus doublet chemotherapy